V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330008636 | 330005429 | null | 50 | Curative (C) | 2014-02-09 | 2014-03-16 | CISPLATIN + VINORELBINE | 02 | N | 330020405 | IVA |
| 330008637 | 330005430 | 1.65 | 46.3 | Palliative (P) | 2016-05-12 | 2016-05-24 | Fludarabine + Melphalan RIC Allo | N | N | 330020409 | R-EPOCH |
| 330008640 | 330005432 | 1.8 | 46.2 | Neo-adjuvant (N) | 2017-12-16 | 2017-12-21 | DACTINOMYCIN + CYCLO + VINCRISTINE | N | N | 330020412 | RMS 2005 TRIAL |
| 330008641 | 330005434 | null | 122 | Disease modification (D) | 2015-09-22 | 2015-10-02 | Cisplatin+Doxorubicin+Etoposide 28d | N | null | 330020420 | CLOFARABINE + CYTARABINE |
| 330008642 | 330005436 | 1.64 | 57 | Neo-adjuvant (N) | 2014-08-12 | 2014-08-15 | PEMBROLIZUMAB | 2 | Y | 330020423 | BEVACIZUMAB + TEMOZOLOMIDE |
| 330008643 | 330005439 | 1.67 | 30.1 | Neo-adjuvant (N) | 2018-01-16 | 2018-03-05 | CISPLATIN + EPIRUBICIN | 02 | null | 330020433 | CYCLO + DOXORUBICIN + VINCRISTINE |
| 330008644 | 330005444 | 1.76 | 90.5 | Not known (9) | 2014-07-08 | 2014-07-08 | Cyclophosphamide High Dose | 02 | null | 330020457 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330008645 | 330005444 | 0 | null | Curative (C) | 2014-05-01 | 2014-05-05 | IDARUBICIN | Y | N | 330020457 | IVADO |
| 330008646 | 330005445 | 1.67 | 106 | Curative (C) | null | 2016-12-27 | Mitotane 3 - 3.5g | null | N | 330020482 | BEVACIZUMAB + IRINOTECAN + TEMOZOLOMIDE |
| 330008647 | 330005446 | 1.83 | 54.9 | Palliative (P) | 2017-02-05 | 2017-03-26 | Alemtuz+Fludara+Melphalan RIC MUD | Y | N | 330020497 | MELPHALAN |
| 330008648 | 330005446 | 1.6 | null | Neo-adjuvant (N) | 2016-08-30 | 2016-11-16 | Nilotinib | N | N | 330020497 | PAZOPANIB |
| 330008649 | 330005446 | null | 69 | Curative (C) | null | 2018-03-01 | IFOSFAMIDE + VINCRISTINE | N | N | 330020497 | IPILIMUMAB |
| 330008650 | 330005448 | null | 52 | Neo-adjuvant (N) | 2016-07-22 | 2016-07-27 | UKALL14- Maintenance | N | null | 330020501 | POMB |
| 330008651 | 330005449 | 1.64 | null | null | 2013-10-19 | 2013-11-22 | Cetuximab + CISPLATIN + FLUOROURACIL | Y | N | 330020510 | TRIPLE INTRATHECAL |
| 330008652 | 330005449 | 1.66 | 77.1 | Curative (C) | null | 2014-10-20 | Triple Intrathecal | null | null | 330020510 | SUNITINIB |
| 330008653 | 330005450 | 1.71 | 8.5 | Curative (C) | 2013-01-26 | 2013-06-23 | BEP 5 Day | N | N | 330020525 | CAPECITABINE + CISPLATIN |
| 330008654 | 330005451 | 1.6 | 54 | Curative (C) | 2015-06-14 | 2015-09-22 | CYTARABINE + MITOXANTRONE | 01 | N | 330020525 | TRASTUZUMAB |
| 330008655 | 330005453 | 0 | 98.9 | Neo-adjuvant (N) | 2014-07-30 | 2014-08-15 | NB BEACON Temozolomide Bevacizumab | N | null | 330020530 | FIGARO TRIAL |
| 330008656 | 330005453 | 1.77 | 80 | Palliative (P) | 2014-06-10 | 2014-06-26 | BCG Intravesical | N | N | 330020530 | IVADO |
| 330008657 | 330005453 | 1.61 | 59 | Curative (C) | 2016-08-28 | 2016-09-10 | Cyclophosphamide + Vincristine | Y | N | 330020530 | CLADRIBINE |
| 330008658 | 330005454 | 1.78 | 75.9 | Curative (C) | 2013-08-07 | 2013-08-07 | VIDE | N | null | 330020552 | IMATINIB |
| 330008659 | 330005454 | 1.75 | 73.5 | Curative (C) | 2015-10-11 | 2015-10-11 | CVP R | N | N | 330020552 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330008660 | 330005455 | 0 | 74.6 | Adjuvant (A) | 2017-08-31 | 2017-08-31 | Gemcitabine + Oxaliplatin | N | N | 330020556 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 330008661 | 330005457 | 1.82 | 11.8 | Adjuvant (A) | 2013-10-20 | 2013-10-20 | IDARUBICIN | N | N | 330020565 | BEP |
| 330008662 | 330005459 | 1.75 | 136.8 | Curative (C) | 2015-10-22 | 2015-10-23 | Cyclophosphamide + Vincristine | N | N | 330020579 | TRIPLE INTRATHECAL |
| 330008663 | 330005460 | 1.61 | 50.7 | Curative (C) | 2016-12-30 | 2017-01-11 | OFATUMUMAB | Y | N | 330020588 | BEVACIZUMAB + IRINOTECAN |
| 330008664 | 330005460 | 1.66 | 69 | Curative (C) | 2018-01-23 | 2018-03-27 | EDP + MITOTANE | 01 | N | 330020588 | GEMCITABINE |
| 330008665 | 330005462 | 1.71 | null | Palliative (P) | 2013-08-14 | 2013-12-16 | PEMBROLIZUMAB | Y | N | 330020590 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330008666 | 330011915 | 0 | null | Curative (C) | 2016-11-02 | 2016-11-02 | Bortezomib +/- Dexamethasone | 02 | N | 330020600 | UKALL2014 |
| 330008667 | 330005463 | 1.78 | 55.4 | Palliative (P) | 2017-04-17 | 2017-04-17 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | N | N | 330020602 | ADE |
| 330008668 | 330008982 | 1.82 | 80 | Palliative (P) | 2018-01-25 | 2018-02-01 | DHAP | Y | N | 330020602 | CAPECITABINE + CARBOPLATIN |
| 330008673 | 330005470 | 0 | 59.4 | Adjuvant (A) | 2017-02-03 | 2017-02-16 | CARBOPLATIN + CETUXIMAB + FU | N | N | 330020665 | BEVACIZUMAB |
| 330008674 | 330005474 | 1.7 | 57.4 | Palliative (P) | 2018-05-12 | 2018-05-12 | FCR Oral - Cycle 2 onwards | 2 | N | 330020669 | PONATINIB |
| 330008677 | 330005478 | 1.6 | 7.5 | Palliative (P) | 2014-01-30 | 2014-02-24 | DHAP | 2 | null | 330020693 | DHAP |
| 330008678 | 330005480 | 1.55 | 7.7 | Palliative (P) | null | 2015-11-16 | Doxorubicin + Gemcitabine | N | N | 330020694 | EMA/CO |
| 330008679 | 330005482 | null | null | Neo-adjuvant (N) | 2017-01-25 | 2017-03-06 | Nintedanib | N | N | 330020710 | VIDE |
| 330008681 | 330005485 | 1.82 | 85.2 | Neo-adjuvant (N) | 2017-04-16 | 2017-04-18 | ADE 10+3+5 | 02 | N | 330020722 | RUXOLITINIB |
| 330008682 | 330008990 | 1.84 | 64.1 | Palliative (P) | 2017-11-25 | 2017-11-26 | IMMUNOGLOBULIN | 2 | N | 330020722 | UKALL XII |
| 330008683 | 330011918 | 1.72 | null | Palliative (P) | 2013-02-16 | 2013-03-05 | IMATINIB | N | N | 330020731 | PEMBROLIZUMAB |
| 330008684 | 330005488 | null | null | Curative (C) | 2018-04-03 | 2018-09-21 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | 330020734 | CARBOPLATIN + PEMETREXED |
| 330008685 | 330005488 | 1.79 | 88.2 | null | 2013-11-06 | 2015-07-15 | Cyclophosphamide High Dose | N | N | 330020734 | CAPECITABINE + LOMUSTINE |
| 330008686 | 330008992 | 1.61 | 87.3 | Palliative (P) | 2014-05-09 | 2014-05-10 | MPT | N | N | 330020744 | LENVATINIB |
| 330008687 | 330005490 | 1.7 | 84.7 | Palliative (P) | 2017-08-25 | 2017-11-03 | BLEOMYCIN + CISPLATIN + ETOPOSIDE | N | N | 330020757 | CAPECITABINE + CISPLATIN |
| 330008688 | 330008993 | 1.83 | null | Adjuvant (A) | 2014-04-10 | 2014-04-22 | Topotecan (intravenous) | 2 | N | 330020761 | LIPOSOMAL DAUNORUBICIN |
| 330008689 | 330010875 | 1.64 | 0 | Palliative (P) | null | 2016-04-04 | FLAG | null | N | 330020767 | CYCLOPHOSPHAMIDE + VINCRISTINE + LIPOSOMAL DOXORUBICIN |
| 330008691 | 330008994 | 1.7 | 67.5 | Palliative (P) | 2014-07-18 | 2014-07-21 | MELPHALAN + TREOSULPHAN | 2 | N | 330020771 | UKALL2014 |
| 330008692 | 330008994 | 1.77 | 33.8 | Palliative (P) | 2017-01-14 | 2017-01-21 | Cyclophosphamide TBI Allograft | 02 | N | 330020771 | BEP |
| 330008693 | 330005493 | 1.82 | 62.5 | Curative (C) | 2016-02-10 | 2016-02-17 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 2 | N | 330020794 | ALEMTUZUMAB |
| 330008694 | 330008995 | 1.71 | 64 | Palliative (P) | 2013-06-06 | 2013-06-17 | VDC | 02 | N | 330020808 | IVA |
| 330008695 | 330008995 | null | 93 | null | null | 2017-07-14 | EMA/CO | null | null | 330020808 | ICE |